Reviva reports first quarter 2025 financial results and recent business highlights

– 446 participants completed the brilaroxazine long-term open-label extension (ole) trial with 156 completing one-year and 301 completing six months of treatment –

RVPH Ratings Summary

RVPH Quant Ranking